Brad MitchellApr 103 minPROG | Sponsors / Upcoming AbstractsUpdate on the Abstracts & Sponsors. Abstracts will be posted before July 13th
Brad MitchellApr 46 minPROG | Earnings Reflection & OBDS industry explanationRelfection on earnings, and exactly why industry will use the OBDS like candy
Brad MitchellMar 205 minPROG | Preecludia ValidatedPreecludia uncertainty is no longer. The product has been reviewed and Progenity's credibility is restored
Brad MitchellMar 136 minPROG | DDS UpdateInsights onto the multi-billion dollar product lines of Progenity. Update on their progress from their flagship therapeutic pill.
Brad MitchellFeb 207 minPROG | Pill of the future, new drug combinationsIL6 suppressant (Tocilizumab) could potentially be used with Progenity's pill to capture $2.5 Billion Annually. DDS | Future applications
Brad MitchellJan 23 minPROG | Future timeline and revenueThis shows the analysis of the future revenue of Progenity and future share price
Brad MitchellDec 26, 20219 minPROG | Understanding topline results before release this weekDescription of the studies for you knowledge and how it will effect share price upon release of results
Brad MitchellDec 19, 20218 minPROG | Stock to double on upcoming topline resultsData is around the corner, details on what to look for and what to expect. Why this pill tech will disrupt healthcare
Brad MitchellDec 8, 20212 minPROG Wednesday Night Twitter Call 12.08.21Itinerary and landing page to discussion of Progenity every wednesday evening at 7pm central time. Audio recording is uploaded afterwards
Brad MitchellDec 5, 202114 minPROG's 4 horsemen to healthcare | Starts with December dataThe future timeline for the adoption of Progenity's products. S-curve uptrend starts this December.
Brad MitchellNov 30, 202146 minItinerary | PROG Wednesday Night Twitter Call Itinerary for upcoming Twitter Spaces call
Brad MitchellNov 28, 202110 min3 Tech Pills & Catalyst TimelinesClarification on the product lines for Progenity and near term catalysts in the future.
Brad MitchellNov 21, 20216 minProgenity | Upcoming catalysts, competition is good newsProgenity to dominate the market during end of year. Price appreciation is on the horizon due to market reevaluation and catalysts ahead.
Brad MitchellNov 7, 202112 minProgenity | PT $25, Buyout $56, no short squeeze or chart analysis, Just ValueOptifinancial Newsletter - Knowledge is power - Brad Mitchell This is not financial advice nor recommendations. This is purely our own...
Brad MitchellOct 3, 20218 minProgenity Inc: A possible short squeeze to $15IN THIS ISSUE Progenity $1.79 Possible short squeeze ahead, alongside strong disruptive technology in the medical field. Look at my last...
Brad MitchellSep 5, 20216 minProgenity and EthereumIN THIS ISSUE Progenity This small biotechnology company has fallen from $15 a share to $1 a share in one year. We think this can go to...
Brad MitchellJul 18, 20217 minProgenity and DisneyIN THIS ISSUE Progenity This company is developing groundbreaking medical technology. Learn why we think now is a good time to buy....
Brad MitchellMay 30, 20217 minProgenity Inc.Please subscribe to us, we are worth your time and will keep you informed! RECAP OF LAST WEEK AND RESULTS: Cassava Sciences This company...